Novartis is entering a new phase of growth powered by blockbuster cancer medicines, radioligand therapy innovation, and precision oncology expansion. Once known for its diversified pharmaceutical portfolio, the company is now increasingly becoming an oncology-focused powerhouse with rapidly growing revenues from next-generation cancer drugs.
In Q1 2026, Novartis reported USD 13.1 billion in total net sales, but the biggest momentum came from its oncology division. The company’s cancer portfolio is now delivering some of the fastest growth rates in the global pharmaceutical industry, driven by therapies like Kisqali, Pluvicto, and Scemblix.
Kisqali Becomes Novartis’ Fastest Growing Breast Cancer Therapy
Kisqali is emerging as one of the world’s leading breast cancer medicines.
The drug generated USD 1.516 billion in Q1 2026 revenue alone, representing a massive 55% year-over-year increase. The therapy is being widely adopted for HR-positive/HER2-negative breast cancer, especially as physicians increasingly shift toward long-term targeted therapies with improved survival outcomes.
Novartis now expects Kisqali to eventually exceed USD 10 billion in peak annual sales, positioning the medicine among the pharmaceutical industry’s future mega-blockbusters.
The company is aggressively expanding Kisqali across both metastatic and early-stage breast cancer treatment settings, helping strengthen its leadership in one of oncology’s largest therapy markets.
| Novartis Drug | Q1 2026 Revenue | YoY Growth | Key Highlight |
|---|---|---|---|
| Kisqali | USD 1.516 Billion | +55% | Breast cancer blockbuster with projected peak sales above USD 10 Billion |
| Pluvicto | USD 642 Million | +70% | Strong growth driven by earlier-stage prostate cancer adoption |
| Scemblix | USD 433 Million | +79% | Rapid expansion in chronic myeloid leukemia treatment |
| Fabhalta | USD 169 Million | +103% | Fastest-growing hematology asset in Novartis portfolio |
| Total Oncology Sales | USD 4.02 Billion | +35% | Oncology becoming Novartis’ strongest growth business |
Pluvicto Strengthens Novartis’ Leadership in Radioligand Therapy
Another major growth engine for Novartis is Pluvicto, its targeted radioligand therapy for advanced prostate cancer.
The drug generated USD 642 million in Q1 2026 sales, growing approximately 70% annually as global demand continued to accelerate. More than 70% of US demand now comes from earlier pre-taxane prostate cancer settings, significantly expanding the therapy’s commercial opportunity.
Radioligand therapy is becoming one of the most promising technologies in modern cancer treatment because it combines precision tumor targeting with radioactive treatment delivery. Instead of attacking healthy and cancerous cells broadly like chemotherapy, these therapies directly bind to tumor cells and deliver radiation precisely where needed.
Industry experts believe radiopharmaceuticals could become one of the next multi-billion-dollar oncology categories over the next decade, and Novartis is positioning itself at the center of that market.
Latest Novartis Oncology News Highlights Pipeline Expansion
Recently, Novartis announced major advancements across its oncology and hematology business, showcasing progress in prostate cancer, breast cancer, leukemia, CAR-T therapy, and autoimmune blood disorders.
The company revealed new developments involving Pluvicto and its next-generation actinium-based radioligand therapies designed to provide stronger and more precise tumor-targeting radiation. Novartis also shared updates involving Kisqali, Scemblix, Fabhalta, Ianalumab, and Rapcabtagene autoleucel, highlighting the company’s broad precision medicine strategy.
The announcement reflects Novartis’ long-term vision of building an integrated oncology ecosystem that combines radiopharmaceuticals, biomarker-driven therapies, cell therapy, and advanced hematology treatments.
Scemblix Continues Explosive Leukemia Growth
Scemblix is quietly becoming another major oncology success story for Novartis.
The leukemia therapy generated USD 433 million in Q1 2026 revenue, growing nearly 79% year over year. The medicine is gaining strong adoption globally because of its differentiated STAMP inhibition mechanism, offering a newer approach for chronic myeloid leukemia treatment.
Novartis has already increased Scemblix’s projected peak annual sales expectations to more than USD 4 billion, reflecting growing physician confidence and expanding patient demand.
Novartis Invests Billions Into Future Cancer Innovation
To support future growth, Novartis recently committed nearly USD 23 billion toward manufacturing and research expansion in the United States.
The investment includes advanced radiopharmaceutical manufacturing facilities, oncology research centers, and next-generation therapy production infrastructure. The company is also expanding its pipeline through acquisitions, biotechnology partnerships, and precision medicine technologies.
Today, Novartis medicines reach nearly 300 million patients globally. But increasingly, oncology is becoming the company’s strongest long-term business driver.
With blockbuster drug growth, expanding radioligand therapy leadership, and one of the pharmaceutical industry’s deepest innovation pipelines, Novartis is positioning itself as one of the defining cancer companies of the next decade.
FDA Expansion Boosts Novartis’ Pluvicto Growth Potential
Novartis received a major regulatory boost after the US FDA expanded approval for Pluvicto to earlier-stage metastatic prostate cancer patients before chemotherapy, significantly increasing the eligible treatment population. The approval was backed by strong Phase 3 trial results showing a 59% reduction in disease progression risk and nearly doubling progression-free survival. The decision further strengthens Novartis’ leadership in the fast-growing radioligand therapy market, where Pluvicto already generated USD 642 million in Q1 2026 sales and is becoming one of the company’s fastest-growing oncology assets.
Get a 360° view of the Pharmaceutical Market with our expert-designed platform. Discover valuable insights, statistical trends, country-specific data, and competitor strategies all in one place. Whether you’re planning a strategy, exploring investment opportunities, or benchmarking your position, the dashboard brings clarity and speed to every decision. Click to visit and access the dashboard; your complete market intelligence hub is ready.
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium